| Literature DB >> 28357917 |
Emelissa J Mendoza1,2, Trina Racine1,3, Gary P Kobinger3,4,5.
Abstract
The 2014-2016 Ebola virus outbreak in West Africa was the deadliest in history, prompting the evaluation of various drug candidates, including antibody-based therapeutics for the treatment of Ebola hemorrhagic fever (EHF). Prior to 2014, only convalescent blood products from EHF survivors had been administered to newly infected individuals as a form of treatment. However, during the recent outbreak, monoclonal antibody cocktails such as ZMapp, ZMAb and MB-003 were either tested in a human clinical safety and efficacy trial or provided to some based on compassionate grounds. This review aims to discuss the evolution of antibody-based treatments for EHF, their clinical trial efficacy and the development of new antibody-based therapies currently advancing in preclinical testing.Entities:
Keywords: Ebola virus; convalescent plasma; monoclonal antibodies; outbreak; pan-ebolavirus; pan-filovirus; therapeutics; clinical trials
Mesh：
Substances：
Year: 2017 PMID： 28357917 DOI： 10.2217/imt-2017-0010
Source DB: PubMed Journal: Immunotherapy ISSN： 1750-743X Impact factor: 4.196